A new model for calculating invasive breast cancer drug risk (the CARE model) gives improved estimates of the number of breast cancers that might develop in African-American women 50 to 79 years of age. An earlier model had been based primarily on data in Caucasian women.
Researchers at the National Cancer Institute worked with colleagues from the Women’s Contraceptive and Reproductive Experiences (CARE) Study, the Women’s Health Initiative, and the Study of generic Tamoxifen and Raloxifene tablets (STAR) trial. Because of the higher accuracy of this model, the NCI authors recommend it for counseling African-American women.
(Source: J Natl Cancer Inst, November 27, 2007.)